Basel Medical Group Ltd
BMGL
$2.02
-$0.17-7.76%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -124.19% | -124.45% | -37.40% | -37.07% | 125.71% |
| Total Depreciation and Amortization | 34.08% | 35.61% | 10.56% | 11.07% | -15.19% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -253.14% | -254.75% | -221.24% | -221.77% | 173.14% |
| Change in Net Operating Assets | -123.75% | -126.22% | 1,804.87% | 1,816.57% | -536.37% |
| Cash from Operations | -2,767.54% | -2,796.81% | 52.95% | 53.73% | -86.19% |
| Capital Expenditure | -137.93% | -141.38% | 100.00% | 100.00% | -70.59% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 565.52% | 568.97% | 100.00% | 100.00% | -70.59% |
| Total Debt Issued | 866.42% | 866.42% | 102.94% | 102.94% | -95.08% |
| Total Debt Repaid | -247.35% | -247.35% | -118.03% | -118.03% | 85.16% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 1,382.48% | 1,382.48% | -67,000.00% | -67,000.00% | -- |
| Cash from Financing | 2,387.03% | 2,412.18% | 22.45% | 22.05% | 65.12% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,130.64% | 2,153.00% | 588.45% | 591.24% | -97.86% |